NV1FGF: Completed Phase III enrollment

sanofi-aventis disclosed that last quarter it completed enrollment in a Phase III trial evaluating intramuscular NV1FGF. The company is developing NV1FGF under a 2000 deal to use Vical's nonviral gene...